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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not male 
circumcision prevents herpes simplex virus type 2 (“HSV-2”) in sexually active males aged 18-
50. 
 
STUDY DESIGN: Review of three English language primary studies published in 2009 and 
2012. 
 
DATA SOURCES: Three randomized control trials analyzing the intervention of circumcision to 
prevent HSV-2 in sexually active males found using Medline and PubMed. 
 
OUTCOMES MEASURED: The main clinical outcome in all studies measured the incidence of 
HSV-2 defined as a sexually transmitted infection with symptoms of visible genital ulceration. 
The outcomes were measure by patient self-report of symptoms, nurse examination, and serum 
samples tested for the HSV-2 antibody utilizing the Kalon Biological assay. Mahiane et al. 
additionally measured the spread of HSV-2 from female to male partners, calculated via self-
report of patients’ sexual behavior including number of partners as a function of time and 
number of sexual contacts with each partner. 
 
RESULTS: In the study by Mehta et al., circumcision was not statistically significant (p = 0.655) 
in preventing HSV-2. In the study by Tobian et al., statistical significance was proven (p= 0.008) 
in the intervention group receiving circumcision. In the study by Mahiane et al., circumcision 
was also found to be statistically significant in preventing HSV-2 per sex act (p= 0.005) and per 
partnership (p=0.001). 
 
CONCLUSIONS:	  The results of two RCTs show circumcision to be an effective intervention in 
the prevention of HSV-2. Because one trial does not reach statistical significance, the overall 
results are inconclusive. In order to improve further research, a larger age and geographical 
population should be recruited. 
 
KEY WORDS: Circumcision, HSV-2, males
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INTRODUCTION 
Herpes simplex virus type 2 (“HSV-2”) is a sexually transmitted infection that is one of 
the main causes of genital lesions8. These lesions present in various stages ranging from vesicles 
to painful erythematous ulcers3. Transmission can occur during sexual contact from either those 
who have visible sores or those who have subclinical viral shedding when sores are not visible1. 
Because transmission can occur when ulcerations are not visible, a high percentage of the 
population is unknowingly HSV-2 positive7. 
Because of high prevalence of HSV-2, physician assistants in a variety of specialties will 
encounter HSV-2 patients. The Center for Disease Control (“CDC”) estimates that 776,000 new 
cases of HSV-2 occur per year resulting in twenty-five percent of the United States population 
having serologic evidence of infection with HSV-27. Although there are no specific estimates 
targeting HSV-2 alone, the CDC estimates the financial burden of treating eight of the most 
common sexually transmitted infections including HSV-2 contracted in one year is fifteen billion 
dollars7. In addition to the cost, the CDC reports that in 2010 there were approximately 232,000 
healthcare visits regarding HSV-27. 
 HSV-2 is spread via exposure to mucosal surfaces or abraded skin sites permitting the 
entry of the virus and the initiation of viral replication3. Symptoms of HSV-2 primary infection 
include painful genital ulcers, dysuria, fever, and tender inguinal lymphadenopathy3. Other 
symptoms include burning, stinging, and neuralgia preceding accompanying attacks1. Lesions 
most often occur on the vermillion border of the lips, the penile shaft, the labia, the perianal skin, 
and the buttocks3. As compared with Herpes simplex virus type 1 (“HSV-1”), HSV-2 has a 
higher genital recurrence rate and the seroprevalence of the virus increases with sexual activity4. 
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The combination of pain, cost, and impaired quality of life place a heavy burden on the infected 
patient. 
 Currently, no definitive cure for HSV-2 exists. Medications used to treat herpes simplex 
outbreaks are anti-viral drugs including Acyclovir, Famciclovir, and Valacyclovir.  These 
medications simply act to decrease pain during an outbreak, shorten the course, and decrease 
viral shedding1.  Patients may use these medications on an episodic basis and are advised to take 
the medication at the onset of prodromal symptoms such as tingling and pruritus1. If taken daily, 
antiviral treatment can reduce transmission of HSV-2 from partner to partner7. Consistent latex 
condom use can also help reduce the spread of HSV-2; however, transmission can still occur in 
genital areas that the condom does not cover1. Patient education and abstinence are among the 
limited options to reduce transmission, as well1. Male circumcision may be used as an alternative 
to oral antiviral medication. This paper evaluates three randomized control trials comparing the 
efficacy of male circumcision to prevent HSV-2. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not male 
circumcision prevents herpes simplex virus type 2 in sexually active males aged 18-50. 
METHODS 
 A set of criteria was selected to perform the research needed for this topic. The criteria 
included a population of male patients aged 18 to 50 who are sexually active. Each study 
selected used the intervention of male circumcision. Comparisons were made in one article 
between groups of males who underwent immediate circumcision and those who had a delayed 
circumcision of twenty-four months. The other two randomized controlled trials compared 
circumcised males to uncircumcised males. Outcomes measured the spread of HSV-2 from 
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female to male partners and the incidence of HSV-2, which is defined as a sexually transmitted 
infection with symptoms of visible ulceration in the selected population. 
 All three studies were randomized control trials published in the English language. The 
articles selected were all published in peer reviewed journals found in Medline and PubMed data 
bases. Key words utilized in the research of this topic included “circumcision,” “HSV-2,” and 
“males.” Articles were selected on the basis of the classification of the study (RCT), clinical 
relevance, and specific patient oriented outcomes that matter (“POEMS”). All three studies 
maintained the baseline inclusion criteria of uncircumcised males. Age groups varied but each 
fell into the broader category range of 18-50. Other studies specified HIV status, residency, and 
hemoglobin levels (See Table-1). Exclusion criteria differed between each study (See Table-1).  
A summary of the statistics reported or used in the trials include p-values, RRR, ARR, and NNT. 
Table 1 displays the demographics and characteristics of the included studies. 
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Table 1: Demographics & Characteristics of Included Studies 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Mahiane 
(2009) 
RCT 2787 18-
24 
Males aged 18-
24 
Uncircumcised 
 0 Male circumcision 
Mehta 
(2012) 
RCT 2044 18-
24 
Males aged 18-
24; 
Uncircumcised 
HIV negative 
Sexually active 
in the last 12 
months; 
Hemoglobin 
more than 9.0 
mmol/l; 
Reside in the 
Kisumu district 
 
Foreskin 
covering less 
than half of the 
glans; 
Bleeding 
disorder; 
Keloid 
formation; 
Other 
conditions that 
might unduly 
increase the 
risks of elective 
surgery; 
Medical 
indication for 
circumcision; 
Participants 
with sexually 
transmitted 
infections were 
deferred until 
treated 
 
0 Medical male 
circumcision (MMC) 
Tobian 
(2009) 
RCT 5534 15-
49 
Males aged 15-
49 
HIV negative 
Uncircumcised 
Preexisting 
positive or 
indeterminate 
HSV-2 status 
0 Male circumcision 
 
OUTCOMES 
 
All outcomes measured were POEMS, each varying by the subjective and objective tools 
related to the particular study. All three studies measured the incidence of HSV-2 defined as a 
sexually transmitted infection with symptoms of visible ulceration, while other articles measured 
additional outcomes.  
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Mahiane, et al. (“Mahiane”), measured the incidence of HSV-2 defined as a sexually 
transmitted infection with symptoms of visible ulceration.  Mahiane measured this outcome by a 
genital examination performed by a clinically trained nurse and by collecting plasma samples 
that were tested using a HSV-2 specific IgG assay to detect HSV-2 antibodies (Kalon HSV-2 
gG2 assay). In addition, the spread of HSV-2 from female to male partners was calculated via 
self-report of patient’s sexual behavior including number of partners as a function of time, 
number of sexual contacts with each partner, reported condom use, and age of each partner.  
In contrast, Mehta, et al. (“Mehta”), and Tobian, et al. (“Tobian”) only measured the 
incidence of HSV-2 defined as a sexually transmitted infection with symptoms of visible 
ulceration.  Mehta utilized patient’s self-reported symptoms, physical exam findings, and serum 
specimens to measure this outcome. Patient’s self-reports included the presence of painful or 
painless sores occurring in the genital region in the past six months and at the current visit. 
Physical exam findings looked at the presence or absence of genital ulcers and the location and 
number of genital ulcers. Trained clinicians performed all genital exams and “clinicians were 
instructed to record any epithelial defect in the skin or mucosa of the genitalia.”6 Both groups 
underwent STI and HIV risk reduction counseling and were provided unlimited supplies of free 
condoms6. Serum specimen tests were collected at baseline, 6, 12, 18, and 24 months from 
randomization6. Specimens were tested for the HSV-2 antibody (Kalon HSV-2 IgG ELISA)6.  
Tobian calculated the incidence by patient’s self-reported symptoms of sexually 
transmitted infection including genital ulceration, urethral discharge, and dysuria8. Patients were 
tested at baseline, 6, 12, and 24 months and were subject to physical exams and interviews8. All 
subjects at each visit were offered HIV testing and counseling, health education, and condoms8. 
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In addition, HSV-2 testing was performed with the use of an enzyme-linked immunosorbent 
assay (ELISA Kalon Biological)8. 
RESULTS 
 Two of the studies included in this report utilized dichotomous data. Mahiane utilized 
continuous data that could not be converted to dichotomous values.  All three studies used 
circumcision as the primary and only intervention, but Mehta and Tobian both included the 
variable of time to differentiate between the intervention group (immediate circumcision) and the 
control group (delayed circumcision), while Mahiane only differentiated control and intervention 
by circumcised or uncircumcised.  
The first randomized control trial by Mehta utilized immediate circumcision as the 
intervention group (n= 1931) compared to delayed circumcision after a 24 month follow up 
period as the control group (n= 1393) and assessed by HSV-2 testing and medical examinations 
during follow ups at 1, 3, 6, 12, 18, and 24 months. This study only included the specific age 
group of 18-24 year old males and had specific inclusion and exclusion criteria as noted in 
Table-1. This study looked at circumcision status and incidence of HSV-2, syphilis, and HIV 
infection. Each group was analyzed separately then HIV incidence was adjusted for HSV-2 
status and genital ulcer disease. 
Table 2: Mehta Results 
CI P-Value RRR (%) ARR (%) NNT 
[0.7-1.25] 0.655 5.2 0.3 1/0.003=334 
 
All patients were analyzed in the group they were originally assigned. Results were 
considered statistically significant at a p value of ≤0.05. Based on the p value, the treatment 
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effect of this intervention is not clinically significant.  The results of this RCT showed a numbers 
needed to treat (“NNT”) of 334; meaning one must treat 334 patients with male circumcision in 
order to prevent HSV-2 in one more patient when compared to no circumcision. The absolute 
risk reduction (“ARR”) shows males who underwent immediate circumcision had a 0.3 times 
absolute decrease in HSV-2 infection rate. In addition, the cumulative incidence of HSV-2 was 
5.8 per 100 person-years among circumcised men and 6.1 per 100 person-years among 
uncircumcised men6. The combination of the statistical insignificance, low ARR, and large 
treatment size show that circumcision was not effective in providing protecting from acquiring 
HSV-2 in this study. 
Tobian enrolled 3393 uncircumcised, HSV-2 negative, male subjects between the ages of 
15-49. Of the 3393 participants, 1684 were assigned immediate circumcision (intervention) 
while 1709 were assigned to undergo circumcision 24 months later (control). Differences 
between the intervention and control groups included higher condom use in the intervention 
group at 6 months, more non-marital sexual relationships in the intervention group, and higher 
rates of alcohol use with sexual intercourse in the control group. In addition, the frequency of 
genital ulcer disease was higher at six months, twelve months, and twenty four months in the 
control group. This study also looked at the effect of male circumcision on the incidence of HPV 
and syphilis infections in addition to HSV-2. Each group was analyzed separately for efficacy 
and HSV-2 and HIV reduction were more broadly touched on.   
All persons whose data was collected in Rakai, Uganda were analyzed in the groups they 
were assigned originally.  The treatment effects show a negative NNT. This value correlates for 
every 40 men treated with circumcision immediately, there was 1 fewer incidence of HSV-2 than 
in the group that was delayed by 24 months. In addition, based on a p-value of ≤0.05 considered 
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statistically significant, the p-value shows that circumcision for the prevention of HSV-2 is 
statistically significant.  The narrow confidence interval further supports the precision of our 
NNT value. Table 3 shows treatment effect as well as p-value and confidence intervals. 
Table 3: Tobian Results 
CI P-Value  RRR (%) ARR (%) NNT 
[0.56-0.92] 0.008 -24.3 -2.5 1/-0.025=-40 
 
 The final study by Mahiane analyzes the effects of male circumcision to prevent HSV-2 
per-sex-act female to male transmission probabilities. Mahiane enrolled 3,274 uncircumcised 
males and randomized participants into two groups; circumcision as the interventional group and 
non-circumcision as the control group.  Data was analyzed via mathematical models of HSV-2 
statuses as functions of time used to estimate the female to male transmission probabilities. Male 
circumcision’s protective effect against HIV transmission was also analyzed separately and in 
relation to HSV-2.  
Unlike the previous two studies, sexual behavior information was collected including 
number of partners as a function of time, number of sexual contacts with each partner, reported 
condom use, and age of each partner.	  The 95% CI of the female to male transmission 
probabilities and relative risks were estimated using the bootstrap re-sampling method with 2000 
replications of the trial data. Based on a p-value of ≤0.05 indicating statistical significance, male 
circumcision’s protective effect against HSV-2 was considered statistically significant for both 
HSV-2 transmission per sex act (p= 0.005) and per partnership (p=0.001). 
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DISCUSSION 
 The aim of this systematic review was to see if male circumcision was a preventative 
option against HSV-2.  Both Mahiane’s and Tobian’s studies proved this prevention option is 
statistically significant. 
 Male circumcision is one of the most common surgical procedures in the United States2. 
This procedure is more commonly performed at birth2. Circumcision is proven to decrease rates 
of urinary tract infections, penile cancer, penile inflammation, penile dermatoses, and lower rates 
of sexually transmitted infections2. In a study with older adults, twenty-three percent of lifetime 
urinary tract infections are due to being uncircumcised2. In the United States, circumcision is an 
elective process, and parents begin to receive counseling regarding the procedure during 
pregnancy2. 
 Decreased risk of sexually transmitted infections, including HIV, HPV, and HSV-2, has 
been proven in various studies2. HIV risk reduction is attributed to the removal of the inner 
mucosa of the foreskin, which has an increase in HIV-1 receptors versus the glans2. The inner 
mucosa of the foreskin is also lightly keratinized which may facilitate the access of HSV-2 and 
HPV to underlying epithelial cell in uncircumcised men2.  
 Circumcision on adolescents and adults is associated with more adverse effects than 
circumcision on a newborn. It is linked with greater risks and cost, a longer recovery period, and 
more pain and discomfort after the procedure2. In addition adolescents who are sexually active 
will not reap the protective benefits of circumcision against sexually transmitted infections.   
Each study reviewed contained limitations. Limitations to all three RCTs include a lack 
of discussion of safety of medical male circumcision or significant side effects due to the 
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procedure. When searching for these articles, it was difficult to find all three articles focusing on 
the prevention of HSV-2 as the sole sexually transmitted infection in the given time frame.  
In the Mehta article, the Kalon test used to analyze serum specimens was found to have a 
lower sensitivity (92%) and specificity (79%) in the Kisumu study. This study had a small age 
range of 18-24 and only used males residing in the Kisimu district of Kenya. These specific 
parameters limit the generalizability of the study.  
The Mahiane study lists that the male population aged from 18-24 was not representative 
of the general male population. The majority of this population was unmarried and reflected a 
short duration of partnerships and low number of sexual contacts. Because the population age 
range was so limited for both Mehta and Mahaine, these studies had a low generalizability to the 
age group in my question.  
Finally, in the Tobian study, the article lists that older subjects were likely to be currently 
or previously married, had a higher number of sexual partners in the previous year, and a higher 
rate of alcohol use with sex in the previous six months. These findings limited the study and may 
have skewed results8. 
CONCLUSION 
 In conclusion, two of the three studies reviewed demonstrated male circumcision was 
effective in the prevention of HSV-2. Due to the fact that one study of the three did not find the 
intervention in question to be effective, the overall evidence is inconclusive. Mehta proved that 
HSV-2 was not prevented by male circumcision and the large numbers needed to treat to have 
any significant impact further supported that finding. 
 In order to improve the clinical outcomes and in efforts to improve further research, 
future studies should reflect a larger geographical population, recruit a larger age range, and 
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should have a standard guideline of evaluating genital ulcerations.   First, a larger geographic 
sample will have a greater world wide effect if studies took place in other countries. It is difficult 
to compare this research and findings to the United States where the majority of circumcision is 
performed at a younger age. Next, a larger age range of uncircumcised men should be recruited. 
In two of the three studies the age range of 18-24 greatly limited the generalizability to the 
population in question of 18-50.  Finally, all studies should create a standard guideline when 
evaluating circumcision to explore possible adverse effects. By including a pain scale for 
circumcision, more data would be available for a numbers need to harm analysis. 
HSV-2 affects over 200,000 Americans and is continuing to be a burden on health care 
workers and the health care system. The genital ulceration as a result of HSV-2 is painful and 
overall decrease the patient’s quality of life. As research continues to grow on the subject, male 
circumcision may become a leader in preventative measures against HSV-2. 
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